Halbert Hargrove Global Advisors
BMRN icon

Halbert Hargrove Global Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Halbert Hargrove Global Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1
Closed -$46 – 395
2026
Q2 		$46 Buy
+1
New +$55 ﹤0.01% 727
2025
Q2 		– Sell
-7
Closed -$514 – 354
2025
Q1 		$514 Buy
+7
New +$471 ﹤0.01% 496

Other funds holding BMRN

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
ARGA Investment Management
ARGA Investment Management Stamford, Connecticut $3.94B AUM 28.9% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Halbert Hargrove Global Advisors's BMRN Position: Q3 2026 in Review

Halbert Hargrove Global Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2026, closing a stake of 1 share — an estimated $46 sold.

Halbert Hargrove Global Advisors first reported a position in BMRN in Q1 2025 and held it in 2 quarters. The position peaked at $514 in Q1 2025. 280 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Halbert Hargrove Global Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Halbert Hargrove Global Advisors sold 1 BioMarin Pharmaceuticals share in Q3 2026, an estimated $46.
  • Halbert Hargrove Global Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Halbert Hargrove Global Advisors's BioMarin Pharmaceuticals position peaked at $514 in Q1 2025.
  • 280 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Halbert Hargrove Global Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.